OrbiMed, biopharma's biggest investor, closes $3.5B in three new private funds
One of the world’s leading biopharma investors has pulled in its next rounds of cash, with the funds planned to go to dozens of companies …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
